24/7 Patient Assistance: 760-405-8205
24/7 Patient Assistance: 760-405-8205
Hospitals & Clinics
specialties & services
Dr. Kamalesh Sankhala graduated from the Dr.S.N. Medical College and completed both his residency and fellowship program at the University of Texas Health Science Center. He is specialized in Medical Oncology and board certified in Oncology. Dr. Sankhala has been in practice for more than 11 years and is affiliated with the University of Texas Health Science Center at Houston. During his career, he has also contributed to several research publications.
Dr. S.N. Medical College
Medical School
University of Texas Health Science Center
Residency
University of Texas Health Science Center
Fellowship
American Board of Internal Medicine - Oncology
University of Texas Health Science Center at Houston
Languages: English/Spanish
(713) 500-4472
7000 Fannin St #1200
Houston, Texas 77030 
Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors.
Mahalingam, D.,Nemunaitis, J. J.,Malik, L.,Sarantopoulos, J.,Weitman, S.,Sankhala, K.,Hart, J.,Kousba, A.,Gallegos, N. S.,Anderson, G.,Charles, J.,Rogers, J. M.,Senzer...; Cancer Chemother. Pharmacol.. 2014 Oct 12.
See more >>
A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma.
Chawla, S. P.,Chua, V. S.,Hendifar, A. F.,Quon, D. V.,Soman, N.,Sankhala, K. K.,Wieland, D. S.,Levitt, D. J.; Cancer. 2014 Oct 15.
See more >>
Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib...
Mahalingam, D.,Malik, L.,Beeram, M.,Rodon, J.,Sankhala, K.,Mita, A.,Benjamin, D.,Ketchum, N.,Michalek, J.,Tolcher, A.,Wright, J.,Sarantopoulos, J.; Cancer Chemother. Pharmacol.. 2014 May 13.
See more >>